News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ACC 2017 More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease Yael L. Maxwell March 09, 2017
News Conference News AHA 2016 Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention Yael L. Maxwell November 29, 2016
News Conference News AHA 2016 My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial Shelley Wood November 28, 2016
News Conference News AHA 2016 Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis Michael O'Riordan November 22, 2016
News Conference News AHA 2016 Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women L.A. McKeown November 17, 2016
News Conference News AHA 2016 PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad Michael O'Riordan November 15, 2016
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016
News Conference News TCT 2016 COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events Michael O'Riordan November 01, 2016
News Conference News ESC 2016 Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say Michael O'Riordan August 27, 2016
News Conference News EAS 2016 Non-HDL Cholesterol, Inflammation Appear to Be Linked in Patients Undergoing Elective PCI Yael L. Maxwell June 08, 2016
News Conference News EAS 2016 Statin-Associated Muscle Symptoms: Real or ‘Artificial,’ Physicians Should Take Time to Manage Patients Yael L. Maxwell June 01, 2016
News Conference News EAS 2016 Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease Yael L. Maxwell May 31, 2016
News Conference News ACC 2016 Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH Michael O'Riordan April 03, 2016
News Conference News AHA 2015 Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact Todd Neale November 12, 2015
News Conference News AHA 2015 AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More Shelley Wood November 05, 2015